At CPHI Milan 2024, Ardena will showcase its latest advancements in drug development and manufacturing, including the launch ...

As CPHI Milan 2024 approaches, Symbiosis Pharmaceutical Services is gearing up to showcase major expansions and innovations ...

During the show, Quotient Sciences CEO Thierry Van Nieuwenhove will share insights on how the company is adapting to new FDA ...

The company will introduce its innovative siliconized moulded glass vials, positioning itself as the only global supplier ...

Bristol Myers Squibb (BMS) acquired Karuna Therapeutics, the developer of KarXT, in a deal worth US $14.0 billion in equity ...

Large reduction in COGS: By 2025, EnzeneX 2.0 expects to produce 40 kg/1000 L batches at $40/gram, redefining FCCM economics. Lower operational costs and higher productivity can lead to up to 50% ...

A head-to-head study has revealed that CSL and Arcturus Therapeutic’s self-amplifying mRNA vaccine can maintain a stronger ...

A head-to-head study has revealed that CSL and Arcturus Therapeutic’s self-amplifying mRNA vaccine can maintain a stronger immune response than a conventional mRNA vaccine for up to one year and at a ...

David Carbone, Director of the James Thoracic Oncology Center and Professor of Internal Medicine at The Ohio State University ...

The FDA has extended its approval of UCB’s BIMZELX to three new indications, extending the use of the drug to a total of four ...

The Swedish biotech company Cellevate has raised €3.2 million in a seed round to fuel the commercialization of its ...

Although vaccines already exist to prevent mpox, high prices and the risk of side effects make it difficult to roll them out ...